Cargando…
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy
BACKGROUND: T cell-redirecting bispecific antibodies establish a connection between endogenous T cells and tumor cells, activating T cells function to eliminate tumor cells without ex vivo genetic alteration or manipulation. Here, we developed a novel dual-specific antibody (DuAb) and an enhanced Du...
Autores principales: | Chen, Manling, Liu, Xiaoyu, Peng, Nan, Zhang, Ting, Mou, Junli, He, Huizhen, Wang, Ying, Xu, Yingxi, Xing, Haiyan, Tang, Kejing, Tian, Zheng, Rao, Qing, Gu, Runxia, Qiu, Shaowei, Wang, Min, Wang, Jianxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367426/ https://www.ncbi.nlm.nih.gov/pubmed/37488603 http://dx.doi.org/10.1186/s40164-023-00423-0 |
Ejemplares similares
-
Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023) -
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
por: Chen, Nianci, et al.
Publicado: (2022) -
Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia
por: Wan, Yuling, et al.
Publicado: (2020) -
Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
por: Chen, Nianci, et al.
Publicado: (2021) -
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
por: Xu, Yingxi, et al.
Publicado: (2019)